Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study

NAZİK BAHÇECİOĞLU S., TURK M., ATAYIK E., PAÇACI ÇETİN G., ARSLAN B., GÜLMEZ İ., ...More

ASTIM ALLERJI IMMUNOLOJI, vol.20, no.2, pp.81-86, 2022 (ESCI, Scopus, TRDizin) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.21911/aai.662
  • Journal Name: ASTIM ALLERJI IMMUNOLOJI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.81-86
  • Keywords: Mepolizumab, mepolizumab adverse events, severe asthma treatment, adverse events, mepolizumab treatment
  • Erciyes University Affiliated: Yes

Abstract

Objective: Mepolizumab, an anti-interleukin 5 humanized monoclonal antibody, which is listed among the treatment options in the Global Initiative for Asthma 2020, is recommended as a step 5 therapy option for patients with uncontrolled severe eosinophilic asthma. Real-life data on adverse drug reactions of mepolizumab are limited. We aimed to analyze the safety profile of mepolizumab retrospectively among patients who were treated with mepolizumab with the diagnosis of eosinophilic severe asthma.